An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in patients with solid tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513716-95-00

Acronym

NECVAX-NEO1-LT

Enrollment

Registered

2024-07-03

Start date

2022-05-16

Completion date

2025-08-18

Last updated

2025-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cutaneous melanoma, Non-Small Cell Lung Cancer, renal cell cancer, Squamous Cell Carcinoma of the Head and Neck, urothelial cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Lithuania

None listed

Source: EU CTIS · Data processed: Feb 4, 2026